Jaguar Health (JAGX) Non-Current Deferred Tax Liability (2017 - 2019)
Jaguar Health's (JAGX) quarterly Non-Current Deferred Tax Liability came in at $20594.0 in Q4 2019, down 97.92% on a QoQ basis from $990549.0 in Q3 2017.
Jaguar Health (JAGX) Non-Current Deferred Tax Liability (2017 - 2019) Analysis & Trends
Jaguar Health (JAGX) has 2 years of Non-Current Deferred Tax Liability data on file, last reported at $20594.0 in Q4 2019.
- On a quarterly basis, Non-Current Deferred Tax Liability changed N/A year-over-year to $20594.0 in Q4 2019; TTM through Dec 2019 was $20594.0, a N/A change from a year earlier, with the FY2019 full-year figure at $20594.0, changed N/A from the prior year.
- Non-Current Deferred Tax Liability for Q4 2019 stood at $20594.0, down from $990549.0 in the prior quarter.
- Over the last five years, Non-Current Deferred Tax Liability for JAGX reached as high as $990549.0 in Q3 2017 and fell as low as $20594.0 in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Nanobiotix | 1,774.59 Bn | 1,774.53 Bn | - |
| 2 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - |
| 3 | BeOne Medicines | 473.53 Bn | 468.74 Bn | 1.35 Bn |
| 4 | Vertex Pharmaceuticals | 123.91 Bn | 116.66 Bn | 2.59 Bn |
| 5 | Regeneron Pharmaceuticals | 71.79 Bn | 63.04 Bn | 3.31 Bn |
| 6 | Belite Bio | 62.15 Bn | 62.15 Bn | - |
| 7 | Argenx Se | 54.75 Bn | 49.57 Bn | 1.41 Bn |
| 8 | Alnylam Pharmaceuticals | 38.10 Bn | 35.10 Bn | 959.66 Mn |
| 9 | Revolution Medicines | 36.11 Bn | 36.11 Bn | - |
| 10 | Jaguar Health | 509,443.80 | -9.55 Mn | 19.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 20,594.00 |
| Dec 31, 2019 | 20,594.00 |
| Sep 30, 2017 | 990,549.00 |
| Sep 30, 2017 | 990,549.00 |